Fibrin Sealant (Tisseel) used in the Experimental Arm.

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Malignant Melanoma

Conditions

Malignant Melanoma, Carcinoma, Squamous Cell

Trial Timeline

Jan 1, 2003 โ†’ Jun 1, 2010

About Fibrin Sealant (Tisseel) used in the Experimental Arm.

Fibrin Sealant (Tisseel) used in the Experimental Arm. is a approved stage product being developed by Baxter for Malignant Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00324272. Target conditions include Malignant Melanoma, Carcinoma, Squamous Cell.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00324272ApprovedCompleted

Competing Products

20 competing products in Malignant Melanoma

See all competitors
ProductCompanyStageHype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabCSPC Pharmaceutical Group LimitedPhase 1/2
40
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Tadalafil + GemcitabineEli LillyPhase 1
33
Patritumab DeruxtecanDaiichi SankyoPhase 1/2
41
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
41
DS-1123Daiichi SankyoPhase 1
33
DS-8201aDaiichi SankyoPhase 1
33
DS-5573aDaiichi SankyoPhase 1
33
DS-6051bDaiichi SankyoPhase 1
33
U3-1565Daiichi SankyoPhase 1
33
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
41
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
enfortumab vedotinAstellas PharmaPhase 1
33
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
77